Phosphate ion
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Phosphate ion
- Accession Number
- DB14523
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Phosphate ion (DB14523)
- Weight
- Average: 94.9714
Monoisotopic: 94.95342 - Chemical Formula
- O4P
- Synonyms
- Orthophosphate
- Phosphate
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium acetate Calcium acetate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium chloride Calcium chloride can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium citrate Calcium citrate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium glucoheptonate Calcium glucoheptonate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium lactate Calcium lactate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium polycarbophil Calcium polycarbophil can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataLiquidguard Liquid 2.5 g/100mL Topical Nano Care Deutschland AG 2020-03-30 Not applicable US 
Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Liquidguard Phosphate ion (2.5 g/100mL) Liquid Topical Nano Care Deutschland AG 2020-03-30 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal phosphates
- Direct Parent
- Non-metal phosphates
- Alternative Parents
- Inorganic oxides
- Substituents
- Inorganic oxide / Non-metal phosphate
- Molecular Framework
- Not Available
- External Descriptors
- trivalent inorganic anion, phosphate ion (CHEBI:18367)
Chemical Identifiers
- UNII
- NK08V8K8HR
- CAS number
- 14265-44-2
- InChI Key
- NBIIXXVUZAFLBC-UHFFFAOYSA-K
- InChI
- InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3
- IUPAC Name
- phosphate
- SMILES
- [O-]P([O-])([O-])=O
References
- General References
- Not Available
- External Links
- PDB Entries
- 117e / 13pk / 151l / 1914 / 1a2y / 1a40 / 1a6q / 1a7k / 1a9o / 1a9p … show 6201 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Hereditary Angioedema (HAE) 2 2 Completed Prevention Breast Cancer 1 2 Completed Treatment Asthma, Allergic 1 2 Completed Treatment Metastatic Breast Cancer 1 2 Unknown Status Treatment Colorectal Cancers 1 1 Completed Basic Science Chronic Heart Failure (CHF) 1 1, 2 Unknown Status Prevention H7N9 Influenza 1 0 Recruiting Treatment HHRH / Hypercalciuria / Hypophosphatemia / Hypovitaminosis D / XLH 1 Not Available Recruiting Basic Science Muscle Acidosis 1 Not Available Unknown Status Other Chronic Kidney Disease (CKD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 1.45 mmol/15mL Solution Oral 57.8 mg/1mL Suspension Oral 15 meq/15mL Liquid Topical 2.5 g/100mL Injection, emulsion Intravenous 150 g Injection, emulsion Intravenous 225 g Injection, emulsion Intravenous 300 g Emulsion Intravenous 150 g Emulsion Intravenous 225 g Injection, emulsion Intravenous 3.66 g Injection, emulsion Intravenous 5.5 g Injection, emulsion Intravenous 7.33 g Injection, emulsion Intravenous 9.16 g Syrup 3.2 meq/5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 ChemAxon pKa (Strongest Acidic) 1.8 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 86.25 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 11.29 m3·mol-1 ChemAxon Polarizability 4.93 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created on July 12, 2018 13:12 / Updated on June 12, 2020 10:53
Integrate DrugBank in your
Precision Medicine software.
Our indications data includes genetic markers, and drug-drug interactions helping you create better health outcomes for patients.